Post-Traumatic Stress Disorder (PTSD)

PTSD — scientific infographic poster
PTSD brain changes — amygdala, hippocampus, prefrontal cortex

Table of Contents

  1. What is PTSD?
  2. DSM-5 Diagnostic Criteria
  3. Four Symptom Clusters
  4. Prevalence and Epidemiology
  5. Neurobiological Underpinnings
  6. Complex PTSD (ICD-11)
  7. Pharmacotherapy
  8. Trauma-Focused Psychotherapy
  9. MDMA-Assisted Therapy
  10. Comorbidities and Special Populations
  11. Research Papers
  12. Connections
  13. Featured Videos

What is PTSD?

Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic event such as a natural disaster, serious accident, terrorist act, war or combat, rape, or other violent personal assault. PTSD was first formally recognized in the DSM-III in 1980, though the clinical syndrome — then called "shell shock" or "combat fatigue" — had been described in veterans since World War I. It affects people of all ages and backgrounds, not just military veterans.

PTSD is distinguished from normal stress reactions by its duration (symptoms persist beyond one month), severity (significant functional impairment), and specific symptom constellation involving re-experiencing, avoidance, negative alterations in cognition and mood, and hyperarousal. Unlike Adjustment Disorder, PTSD requires a formally "traumatic" Criterion A stressor — not merely a difficult life event.

Back to Table of Contents

DSM-5 Diagnostic Criteria

The DSM-5 (2013) defines PTSD under "Trauma- and Stressor-Related Disorders." The diagnosis requires all of the following:

Criterion A: Traumatic Stressor

Exposure to actual or threatened death, serious injury, or sexual violence via one or more of these routes:

This Criterion A requirement is the formal boundary that distinguishes PTSD from Adjustment Disorder. A painful divorce, job loss, or financial crisis — while genuinely distressing — does not meet Criterion A unless it involved actual or threatened death, serious injury, or sexual violence.

Additional Criteria

Specifiers include: With dissociative symptoms (depersonalization or derealization) and With delayed expression (full criteria not met until at least 6 months after the event).

Back to Table of Contents

Four Symptom Clusters

Criterion B: Intrusion Symptoms (1 or more required)

Intrusion symptoms represent the involuntary, unwanted re-experiencing of the trauma:

Criterion C: Avoidance (1 or more required)

Persistent effortful avoidance of stimuli associated with the traumatic event:

Avoidance is the mechanism that prevents natural recovery. By not processing the memory, the fear network remains active and the memory is never contextualized as "past." This is why avoidance-based coping perpetuates PTSD and why all effective trauma therapies involve confronting rather than avoiding the memory.

Criterion D: Negative Alterations in Cognitions and Mood (2 or more required)

These symptoms represent the persistent emotional and cognitive consequences of trauma — often the hardest for loved ones to recognize as PTSD symptoms rather than character flaws:

Criterion E: Alterations in Arousal and Reactivity (2 or more required)

The hyperarousal cluster reflects the nervous system remaining in a state of threat-readiness long after the danger has passed:

Back to Table of Contents

Prevalence and Epidemiology

PTSD is more common than many people realize, affecting millions worldwide. Rates vary sharply by trauma type and population group:

General Population

High-Risk Populations

Risk and Resilience Factors

Importantly, PTSD does not develop in the majority of trauma-exposed individuals. Approximately 70-80% of adults experience at least one Criterion A event in their lifetime, yet only about 6.8% develop PTSD. Resilience is the norm; PTSD represents a failure of normal recovery processes, not a character weakness or inevitability of trauma.

Back to Table of Contents

Neurobiological Underpinnings

PTSD represents a disorder of fear memory — specifically, a failure of fear extinction and contextual memory. Four brain regions and one endocrine system are central to understanding its biology:

Amygdala Hyperreactivity

The amygdala encodes emotional memories, particularly fear. In PTSD, the amygdala is hyperreactive to trauma-related cues — responding as if the threat is present even when it is not. Neuroimaging studies (Rauch, Shin, and Phelps, 2006) consistently show increased amygdala activation to threat cues in PTSD versus controls. This hyperactivity drives the intrusion and hyperarousal symptom clusters. The amygdala's "smoke detector" function is set permanently to high sensitivity, triggering a full threat response to stimuli that merely resemble elements of the original trauma.

Hippocampal Volume Reduction

The hippocampus is critical for contextual memory — encoding not just "what happened" but "when and where," allowing the brain to recognize that a past threat is not a current one. In PTSD, multiple studies show 5-20% reduction in hippocampal volume. This means trauma memories lack proper temporal context: a car backfiring does not register as "a car backfiring in 2024" but triggers the amygdala as if it were gunfire years earlier. The chicken-and-egg debate (pre-existing smaller hippocampus as risk factor vs. stress-induced reduction) has largely been resolved by prospective twin studies: both mechanisms contribute.

Prefrontal Cortex Hypoactivity

The medial prefrontal cortex (mPFC), particularly the ventromedial PFC, normally inhibits amygdala activity and facilitates fear extinction — the learned suppression of fear responses to stimuli that are no longer dangerous. In PTSD, mPFC activity is reduced, impairing this top-down inhibitory control. This is the neurological rationale for exposure-based therapies: they repeatedly activate the mPFC-amygdala extinction circuit, strengthening it through learning until it can reliably inhibit the fear response.

HPA Axis Dysregulation — Low Cortisol in Chronic PTSD

One of the most counterintuitive findings in PTSD biology: unlike major depression (which features elevated cortisol), chronic PTSD is typically associated with low basal cortisol and enhanced cortisol suppression on the low-dose dexamethasone suppression test — indicating a hypersensitive HPA negative feedback loop. Yehuda's pioneering research showed this clearly. The low cortisol state reflects both enhanced glucocorticoid receptor sensitivity and a failure to mobilize the cortisol stress response appropriately. This has treatment implications: hydrocortisone administration before extinction training has shown promise in early trials.

Noradrenergic Dysregulation

The locus coeruleus-norepinephrine system is chronically over-activated in PTSD, driving hyperarousal, exaggerated startle, and trauma nightmares. This is the mechanism underlying the efficacy of prazosin (an alpha-1 adrenergic antagonist) for trauma nightmares: by blocking noradrenergic signaling during REM sleep, it reduces nightmare frequency and intensity. The noradrenergic system also explains why beta-blockers given acutely after trauma may reduce PTSD risk by blunting the norepinephrine surge that consolidates traumatic memories — though this remains investigational.

Back to Table of Contents

Complex PTSD (ICD-11)

The ICD-11 (2019) introduced Complex PTSD (CPTSD) as a separate diagnostic category — recognition of decades of clinical observation that survivors of prolonged, repeated interpersonal trauma (childhood abuse, prolonged domestic violence, torture, captivity) present with a more severe and pervasive syndrome than standard PTSD describes.

CPTSD Diagnostic Requirements

CPTSD requires meeting all PTSD criteria plus disturbances in self-organization (DSO) across three domains:

DSM-5-TR Status and the BPD Debate

CPTSD is not in the DSM-5 or DSM-5-TR. This represents a genuine ongoing scientific debate. Critics argue that CPTSD symptoms overlap substantially with Borderline Personality Disorder (BPD) — both involve affect dysregulation, negative self-concept, and relationship difficulties. Proponents (Brewin et al, 2017; the ICD-11 working group) argue the two are empirically distinct: CPTSD lacks BPD's identity disturbance, frantic abandonment avoidance, self-harm behaviors, and rapidly shifting self-image, and has a more coherent trauma etiology with a different temporal course. The practical implication for clinicians: a patient with PTSD plus pervasive shame, chronic emptiness, and relationship avoidance (rather than BPD's relationship intensity and instability) likely has CPTSD by ICD-11 criteria and may need stabilization-phase work before intensive trauma processing — standard Prolonged Exposure may be less effective as a standalone without prior affect regulation and safety work.

Back to Table of Contents

Pharmacotherapy

Medications for PTSD are adjunctive — they reduce symptom severity but do not process the trauma. The VA/DoD 2023 Clinical Practice Guidelines recommend trauma-focused psychotherapy as first-line; medications are recommended when therapy is unavailable, declined, or insufficient.

FDA-Approved Medications

Both SSRIs primarily address hyperarousal and re-experiencing; their effect on the avoidance and numbing clusters is less robust — which is why combining them with trauma-focused psychotherapy typically produces better outcomes than either alone.

Prazosin for Trauma Nightmares

Prazosin is an alpha-1 adrenergic receptor antagonist used at CNS-active doses specifically to reduce trauma nightmares. Dosing: typically 1-5 mg at bedtime, titrated up to 15 mg if tolerated; always start at 1 mg to avoid orthostatic hypotension. Mechanism: by blocking norepinephrine signaling during REM sleep, prazosin reduces the intensity and frequency of trauma nightmares — without sedation or blunting of daytime emotions. The Raskind et al JAMA 2018 randomized trial in veterans found prazosin superior to placebo on nightmare frequency, sleep quality, and overall PTSD symptom severity. The VA/DoD 2023 guidelines strongly recommend prazosin specifically for sleep disturbance and nightmares in PTSD.

Second-Line and Adjunctive Medications

Back to Table of Contents

Trauma-Focused Psychotherapy

Multiple meta-analyses confirm that trauma-focused therapies outperform supportive therapy, non-trauma-focused CBT, and waitlist control by a large margin (effect sizes d = 1.0-1.8 vs waitlist, d = 0.5-0.8 vs active non-trauma-focused comparison). The key feature of effective PTSD treatment is direct engagement with the traumatic memory — either through exposure or cognitive restructuring — rather than supportive discussion of symptoms at a distance.

Prolonged Exposure (PE) — Foa et al

Developed by Edna Foa at the University of Pennsylvania, PE is based on emotional processing theory: traumatic memories fail to integrate into normal memory networks because they are avoided. PE has two core components:

Format: 8-15 sessions of approximately 90 minutes. Effect sizes: d = 1.08 to 1.82 versus waitlist — among the largest effect sizes in all of psychotherapy research. PE has the strongest and most extensive evidence base of any PTSD treatment modality.

Cognitive Processing Therapy (CPT) — Resick et al

Developed by Patricia Resick, CPT targets the cognitive disruptions trauma produces — specifically stuck points: maladaptive beliefs that interfere with recovery. Common stuck points include: "It was my fault," "I should have done something," "The world is completely unsafe," "I am permanently damaged," "I cannot trust anyone." CPT teaches patients to identify these beliefs, examine the evidence, and develop more balanced and accurate perspectives through structured worksheets and dialogue.

Eye Movement Desensitization and Reprocessing (EMDR) — Shapiro

Developed by Francine Shapiro in 1989, EMDR involves having the patient briefly focus on the traumatic memory while simultaneously engaging in bilateral stimulation — typically side-to-side eye movements following the therapist's finger, but also alternating taps or auditory tones. The trauma memory is processed through repeated short exposures interspersed with bilateral stimulation sets.

Trauma-Focused CBT for Children (TF-CBT)

The evidence-based adaptation of trauma therapy for children ages 3-18 involves parallel child and parent sessions, with gradual trauma narration, cognitive coping skills, and psychoeducation. The non-offending caregiver component is a key differentiator from adult treatments — caregiver involvement significantly improves child outcomes and is a core component of the model, not optional.

Back to Table of Contents

MDMA-Assisted Therapy (Phase 3)

The most significant development in PTSD treatment in decades is MDMA-assisted therapy (MDMA-AT), investigated by the Multidisciplinary Association for Psychedelic Studies (MAPS) through Phase 2 open-label studies and two Phase 3 randomized controlled trials.

MAPS MAPP1 Phase 3 Trial (Mitchell et al, Nature Medicine 2021)

The pivotal Phase 3 trial enrolled 90 patients with severe, chronic PTSD (mean CAPS-5 score 44.7 — in the severe range; many had failed prior treatments). Participants received 3 MDMA sessions (80 mg with an optional 40 mg booster dose) or placebo, each within a structured 8-hour therapy session, supported by 12 non-drug integrative therapy sessions. Results:

Proposed Mechanism

MDMA's therapeutic mechanism in trauma processing involves several converging effects:

Regulatory Status as of 2025

An FDA advisory committee reviewed MAPS data in June 2024 and voted against recommending approval, citing concerns about trial design (functional unblinding given MDMA's subjective effects) and requests for additional confirmatory data. MDMA-AT remains unapproved by the FDA as of 2025 but is available through expanded access protocols for treatment-resistant cases. Australia approved MDMA-AT for PTSD in 2023, becoming the first country to authorize a psychedelic-assisted therapy for a psychiatric condition. The Phase 3 data represent a transformative signal for the field even as the US regulatory path remains uncertain.

Back to Table of Contents

Comorbidities and Special Populations

Common Comorbidities

Veterans and Military Personnel

Combat PTSD has unique clinical features: moral injury (having committed acts or witnessed failures that violate one's moral code, beyond simple fear-based threat), military sexual trauma (MST), traumatic brain injury co-occurrence, and powerful institutional and cultural barriers to help-seeking. The VA/DoD 2023 Clinical Practice Guidelines represent the largest investment in PTSD treatment research in any population and are updated regularly as evidence accumulates.

Perinatal PTSD

Childbirth can constitute a Criterion A traumatic event — particularly in cases involving perceived threat to life, emergency procedures, loss of control, or obstetric violence. Perinatal PTSD is estimated at 3-4% of deliveries overall and up to 30% in women with high-risk deliveries or prior trauma histories. It is frequently unrecognized by healthcare providers and can interfere with mother-infant bonding, breastfeeding initiation, and subsequent reproductive decisions.

Moral Injury

Moral injury — the damage done when a person does something, fails to prevent something, or witnesses something that violates their deeply held moral beliefs — is distinct from but often co-occurs with PTSD in veterans, healthcare workers, and first responders. It is characterized by shame, guilt, spiritual crisis, and loss of meaning rather than fear-based symptoms. Standard exposure-based PTSD treatments targeting fear extinction are less effective for moral injury; Adaptive Disclosure Therapy and other meaning-focused approaches have been developed specifically to address it.

Back to Table of Contents

Research Papers

Background

PTSD was formally introduced into the DSM-III in 1980, largely driven by advocacy from Vietnam War veterans and their clinicians. The diagnosis unified previously fragmented labels — shell shock, combat fatigue, traumatic neurosis, rape trauma syndrome — under a single diagnostic framework. The past 45 years have produced explosive growth in PTSD neuroscience and treatment research, transforming understanding of trauma from a narrative of "psychological weakness" to a diagnosable disorder with neurobiological underpinnings, validated assessment tools, and a range of effective treatments. The field continues to evolve rapidly, particularly in the areas of psychedelic-assisted therapies, biomarker research, and precision medicine approaches to matching patients to optimal treatments.

Key Research Papers

  1. Mitchell JM et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. 2021;27:1025-1033.
  2. Foa EB et al. Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring. Journal of Consulting and Clinical Psychology. 2005;73(5):953-964.
  3. Resick PA et al. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. Journal of Consulting and Clinical Psychology. 2002;70(4):867-879.
  4. Shapiro F. Eye movement desensitization: A new treatment for post-traumatic stress disorder. Journal of Behavior Therapy and Experimental Psychiatry. 1989;20(3):211-217.
  5. Brady K et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283(14):1837-1844.
  6. Tucker P et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry. 2001;62(11):860-868.
  7. Raskind MA et al. Trial of prazosin for post-traumatic stress disorder in military veterans. JAMA. 2018;320(8):753-763.
  8. Yehuda R et al. Post-traumatic stress disorder. Nature Reviews Disease Primers. 2015;1:15057.
  9. Rauch SL, Shin LM, Phelps EA. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research — past, present, and future. Biological Psychiatry. 2006;60(4):376-382.
  10. Brewin CR et al. Proposal for inclusion of complex PTSD in ICD-11. World Psychiatry. 2017;16(1):112-113.
  11. Kessler RC et al. Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry. 1995;52(12):1048-1060.
  12. VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Version 4.0 (2023).

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents